Use of bortezomib in B-cell non-Hodgkin’s lymphoma

Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases

1997 • 4,661 citations

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

2003 • 3,966 citations

STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES

1996 • 2,408 citations

The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB

1994 • 2,124 citations

Protein degradation and protection against misfolded or damaged proteins

2003 • 2,022 citations

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

2001 • 1,520 citations

How Proteolysis Drives the Cell Cycle

1996 • 1,277 citations

Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells

2001 • 1,035 citations

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

2004 • 971 citations

Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

2002 • 771 citations

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

2002 • 759 citations

Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids

1998 • 674 citations

Molecular Cloning of the Chromosomal Breakpoint of B-Cell Lymphomas and Leukemias with the t(11;14) Chromosome Translocation

1984 • 671 citations

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

2004 • 593 citations

Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

2003 • 591 citations

Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

2004 • 589 citations

Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

2005 • 581 citations

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341

2003 • 572 citations

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

2005 • 558 citations

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

2005 • 554 citations

Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

2004 • 531 citations

Apoptosis: Activate NF-κB or die?

1997 • 524 citations

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

2005 • 467 citations

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

2002 • 446 citations

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

2004 • 440 citations

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

2003 • 388 citations

Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up

2004 • 364 citations

Inhibition of Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis

2003 • 325 citations

Nuclear Factor-κB Activation: A Question of Life or Death

2002 • 241 citations

Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity

2006 • 173 citations

The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival.

2003 • 155 citations

Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias

1993 • 152 citations

New insights into proteasome function: from archaebacteria to drug development

1995 • 136 citations

Coding sequence of the overexpressed transcript of the putative oncogene PRAD1/cyclin D1 in two primary human tumors.

1993 • 107 citations

Abnormal expression of apoptosis‐related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma

2003 • 105 citations

Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

2005 • 94 citations

Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).

2004 • 74 citations

Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer

2003 • 65 citations

Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab

2003 • 52 citations

In Silico Simulation of Inhibitor Drug Effects on Nuclear Factor-κB Pathway Dynamics

2004 • 48 citations

Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells

2003 • 30 citations

Phase I/II study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma.

2004 • 24 citations

Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study

2005 • 22 citations

Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

2005 • 18 citations

Phase II Study of Bortezomib in Waldenstrom’s Macroglobulinemia: Results of WMCTG Trial 03-248.

2005 • 13 citations

Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDS-Related Lymphoma (ARL).

2004 • 13 citations

Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).

2004 • 10 citations

A Phase 2 Study of Bortezomib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

2005 • 4 citations